Annex III questions and answers – Annual fees and remuneration
Annex III questions and answers – Annual fees and remuneration
Annex III questions and answers – Annual fees and remuneration
Annex II questions and answers – Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products
Annex I questions and answers – Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use
New fee regulation working arrangements
CHMP PROM minutes for the meeting on 02 December 2024
Human medicines European public assessment report (EPAR): Ocaliva, obeticholic acid, Date of authorisation: 12/12/2016, Revision: 21, Status: Revoked
PSUSA/00010665/202405
PSUSA/00010525/202404
PSUSA/00002001/202404
Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Date of authorisation: 18/11/2021, Revision: 8, Status: Withdrawn